MetLife Investment Management’s Icosavax, Inc. Common Stock ICVX Stock Holding History

MetLife Investment Management’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,059	Closed	-$237K	–	2845
2023 Q4	$237K	Buy	15,059 +2,361	+19%	+$22.7K	﹤0.01%	2142
2023 Q3	$98.4K	Hold	12,698	–	–	﹤0.01%	2586
2023 Q2	$126K	Hold	12,698	–	–	﹤0.01%	2545
2023 Q1	$73.6K	Hold	12,698	–	–	﹤0.01%	2662
2022 Q4	$101K	Buy	+12,698	New	+$54.5K	﹤0.01%	2590
2022 Q2	–	Sell	-15,326	Closed	-$108K	–	2925
2022 Q1	$108K	Buy	15,326 +10,069	+192%	+$158K	﹤0.01%	2611
2021 Q4	$120K	Hold	5,257	–	–	﹤0.01%	2338
2021 Q3	$156K	Buy	+5,257	New	+$178K	﹤0.01%	2239

MetLife Investment Management's ICVX Position: Q1 2024 in Review

MetLife Investment Management sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 15,059 shares — an estimated $237K sold.

MetLife Investment Management first reported a position in ICVX in Q3 2021 and held it in 8 quarters. The position peaked at $237K in Q4 2023. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

MetLife Investment Management reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
MetLife Investment Management sold 15,059 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $237K.
MetLife Investment Management first reported a position in Icosavax, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
MetLife Investment Management's Icosavax, Inc. Common Stock position peaked at $237K in Q4 2023.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on MetLife Investment Management's 13F filing for Q1 2024, filed 14 May 2024.